Detalhe da pesquisa
1.
Tissue Resistance Decrease during Irreversible Electroporation of Pancreatic Cancer as a Biomarker for the Adaptive Immune Response and Survival.
J Vasc Interv Radiol
; 34(10): 1777-1784.e4, 2023 10.
Artigo
Inglês
| MEDLINE | ID: mdl-37391072
2.
MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE): a single-centre, open-label, randomised phase 2 trial.
Lancet Gastroenterol Hepatol
; 9(5): 448-459, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38513683
3.
Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes.
Oncoimmunology
; 12(1): 2204745, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37123045
4.
Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition.
Oncoimmunology
; 12(1): 2233403, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37470057
5.
Local delivery of low-dose anti-CTLA-4 to the melanoma lymphatic basin leads to systemic Treg reduction and effector T cell activation.
Sci Immunol
; 7(73): eabn8097, 2022 07 15.
Artigo
Inglês
| MEDLINE | ID: mdl-35857579
6.
Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Metastatic Pancreatic Ductal Adenocarcinoma (PANFIRE-III). A Phase-I Study Protocol.
Cancers (Basel)
; 13(15)2021 Aug 02.
Artigo
Inglês
| MEDLINE | ID: mdl-34359801